Yuecheng Yu

Yuecheng Yu

Auto-generated profile, based on publicly available information

Yuecheng Yu

Center of Hepatology and Department of Infectious Disease, Jinling Hospital Affiliated to School of Medicine, Nanjing University, Nanjing, China

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2017 in Hepatology International
Verified
Journal Article
Open access
PDF file
DGDrug-induced Liver Injury (DILI) Study Group
Drug-induced Liver Injury (DILI) Study Group
YYYue-Cheng Yu
Yue-Cheng Yu
C(Chinese Society Of Hepatology (Csh)
Chinese Society Of Hepatology (Csh)
C(Chinese Medical Association (CMA)
Chinese Medical Association (CMA)
YMYimin Mao
Yimin Mao
HZHui Zhuang
Hui Zhuang
Drug-induced liver injury (DILI) is an important clinical problem, which has received more attention in recent decades. It can be induced by small chemical molecules, biological agents, traditional Chinese medicines (TCM), natural medicines (NM), health products (HP), and dietary supplements (DS). Idiosyncratic DILI is far more common than intrinsic DILI clinically and can be classified into hepatocellular injury, cholestatic injury, hepatocellular-cholestatic mixed injury, and vascular injury based on the types of injured target cells. The CSH guidelines summarized the epidemiology, pathogenesis, pathology, and clinical manifestation and gives 16 evidence-based recommendations on diagnosis, differential diagnosis, treatment, and prevention of DILI.

31 March 2021 in Journal of Clinical and Translational Hepatology
Verified
Journal Article
Open access
WZWei Zhang
Wei Zhang
LLLu Liu
Lu Liu
MZMing Zhang
Ming Zhang
FZFeng Zhang
Feng Zhang
CPChunyan Peng
Chunyan Peng
YZYuzheng Zhuge
Yuzheng Zhuge
Hepatic sinusoidal obstruction syndrome (HSOS) is caused by toxic injury to sinusoidal endothelial cells in the liver. The intake of pyrrolizidine alkaloids (PAs) in some Chinese herbal remedies/plants remains the major etiology for HSOS in China. Recently, new diagnostic criteria for PA-induced HSOS (i.e. PA-HSOS) have been developed; however, the efficacy has not been clinically validated. This study aimed to assess the performance of the Nanjing criteria for PA-HSOS.

12 March 2021 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
SLShan-Shan Li
Shan-Shan Li
MNMing Niu
Ming Niu
JJJing Jing
Jing Jing
YHYing Huang
Ying Huang
ZZZi-Teng Zhang
Zi-Teng Zhang
JWJia-Bo Wang
Jia-Bo Wang
Objectives: Autoimmune hepatitis (AIH) can progress into severe outcomes, i.e., decompensated cirrhosis, from remarkable and persistent inflammation in the liver. Considering the energy-expending nature of inflammation, we tried to define the metabolomics signatures of AIH to uncover the underlying mechanisms of cirrhosis development and its metabolic biomarkers.Methods: Untargeted metabolomics analysis was performed on sera samples from 79 AIH patients at the stages (phenotypes) of non-cirrhosis (n = 27), compensated cirrhosis (n = 22), and decompensated cirrhosis (n = 30). Pattern recognition was used to find unique metabolite fingerprints of cirrhosis with or without decompensation.Results: Out of the 294 annotated metabolites identified, 2 metabolic fingerprints were found associated with the development of cirrhosis (independent of the decompensated state, 42 metabolites) and the evolution of decompensated cirrhosis (out of 47 metabolites), respectively. The cirrhosis-associated fingerprints (eigenmetabolite) showed better capability to differentiate cirrhosis from non-cirrhosis patients than the aminotransferase-to-platelet ratio index. From the metabolic fingerprints, we found two pairs of metabolites (Mesobilirubinogen/6-Hydroxynicotinic acid and LysoPA(8:0/0:0)/7alpha-Hydroxycholesterol) calculated as ratio of intensities, which revealed robust abilities to identify cirrhosis or predict decompensated patients, respectively. These phenotype-related fingerprint metabolites featured fundamental energy supply disturbance along with the development of AIH cirrhosis and progression to decompensation, which was characterized as increased lipolysis, enhanced proteolysis, and increased glycolysis.Conclusions: Remodeling of metabolism to meet the liver inflammation-related energy supply is one of the key signatures of AIH in the development of cirrhosis and decompensation. Therefore, drug regulation metabolism has great potential in the treatment of AIH.

8 March 2021 in Hepatology Communications
Verified
Journal Article
Open access
PDF file
YHYing Huang
Ying Huang
MNMing Niu
Ming Niu
JJJing Jing
Jing Jing
ZZZi‐Teng Zhang
Zi‐Teng Zhang
XZXu Zhao
Xu Zhao
JWJia-Bo Wang
Jia-Bo Wang
Alcohol‐associated liver disease (ALD) is caused by alcohol metabolism’s effects on the liver. The underlying mechanisms from a metabolic view in the development of alcohol‐associated liver cirrhosis (ALC) are still elusive. We performed an untargeted serum metabolomic analysis in 14 controls, 16 patients with ALD without cirrhosis (NC), 27 patients with compensated cirrhosis, and 79 patients with decompensated ALC. We identified two metabolic fingerprints associated with ALC development (38 metabolites) and those associated with hepatic decompensation (64 metabolites) in ALC. The cirrhosis‐associated fingerprint (eigenmetabolite) showed a better capability to differentiate ALC from NC than the aspartate aminotransferase–to‐platelet ratio index score. The eigenmetabolite associated with hepatic decompensation showed an increasing trend during the disease progression and was positively correlated with the Model for End‐Stage Liver Disease score. These metabolic fingerprints belong to the metabolites in lipid metabolism, amino acid pathway, and intermediary metabolites in the tricarboxylic acid cycle. Conclusion: The metabolomic fingerprints suggest the disturbance of the metabolites associated with cellular energy supply as an underlying mechanism in the development and progression of alcoholic cirrhosis.

11 March 2024 in Hepatology Communications
Verified
Journal Article
Open access
XZXinyan Zhao
Xinyan Zhao
YWYan Wang
Yan Wang
RLRongtao Lai
Rongtao Lai
XWXiaojin Wang
Xiaojin Wang
YYYuecheng Yu
Yuecheng Yu
JJJidong Jia
Jidong Jia
Background & Aims: The Revised Electronic Causality Assessment Method (RECAM), a computerized update of the Roussel Uclaf Causality Assessment Methodology (RUCAM), was recently proposed. In this study, we validated and compared the utility of the RECAM and RUCAM in Chinese patients with a single conventional or herbal agent-induced liver injury. Methods: In this retrospective multicenter cohort of well-established DILI and non-DILI patients from 5 centers in China, the diagnostic performance of the RUCAM and RECAM was compared by AUC analysis. The consistency was evaluated by weighted kappa. The major causes of discrepancy were explored. Results: A total of 481 DILI and 100 non-DILI patients were included. In total, 62.6% of the DILI cases were induced by conventional agents, and 37.4% were induced by herbs. The RECAM had relatively higher AUC than RUCAM for overall [0.947 (0.926–0.964) vs. 0.867 (0.836–0.893), p=0.0016], conventional agents [0.923 (0.890–0.949) vs. 0.819 (0.775–0.858), p=0.0185], and herbs [0.972 (0.941–0.989) vs.0.911 (0.866–0.944), p=0.0199]. Latency, scores associated with hepatitis B, and hepatotoxicity information of the insulting drugs were the 3 main causes for the inconsistency between RECAM and RUCAM scores. Conclusions: The RECAM had relatively better diagnostic performance than RUCAM, with a higher AUC for Chinese DILI patients. Timely updates of the LiverTox category and refinement of serum markers to exclude hepatitis B activity would further improve the applicability of RECAM in areas where the use of herbs and resolution of past HBV infections are common.

21 January 2018 in World Journal of Gastroenterology
Verified
Journal Article
Open access
JWJian-Wei Wu
Jian-Wei Wu
YYYue-Cheng Yu
Yue-Cheng Yu
XQXian-Li Qu
Xian-Li Qu
YZYan Zhang
Yan Zhang
HGHong Gao
Hong Gao
Optimization of hepatobiliary phase delay time of Gd-EOB-DTPA-enhanced magnetic resonance imaging for identification of hepatocellular carcinoma in patients with cirrhosis of different degrees of severity